Latest Breaking News On - Jeffreyw albers - Page 1 : comparemela.com

Eagle Asset Management Inc Boosts Stake in Blueprint Medicines Co (NASDAQ:BPMC)

Eagle Asset Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,396 shares of the biotechnology company’s stock after acquiring an additional 22,279 […]

United statesAriel hurleyStifel nicolausPiper sandlerJeffreyw albersAxiom investorsExchange commissionEagle asset management incBrown advisory incNeedham companyBlueprint medicines corporationBlueprint medicines coNorges bankEagle asset managementBlueprint medicinesFree report

The Goldman Sachs Group Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $168 00

The Goldman Sachs Group Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $168 00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealand generalNew zealandMichael landsittelJeffreyw albersPiper sandlerNeedham companyBlueprint medicines corporationBlueprint medicines company profileSecurities exchange commissionPolar capital holdings plcVanguard group incGoldman sachs groupWellington management groupBlueprint medicinesFree report

Blueprint Medicines Co Forecasted to Earn FY2027 Earnings of $5 34 Per Share (NASDAQ:BPMC)

Blueprint Medicines Co Forecasted to Earn FY2027 Earnings of $5 34 Per Share (NASDAQ:BPMC)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesLeerink partnrsJeffreyw albersChristopherk murrayBlueprint medicines corporationPolar capital holdings plcBlueprint medicines coNeedham companyNorges bankBlueprint medicines company profileGoldman sachs groupSecurities exchange commissionBlueprint medicinesFree reportBlueprint medicineGet free report

The Goldman Sachs Group Raises Blueprint Medicines (NASDAQ:BPMC) Price Target to $168 00

The Goldman Sachs Group Raises Blueprint Medicines (NASDAQ:BPMC) Price Target to $168 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesStifel nicolausJeffreyw albersTraceyl mccainUs bancorpSecurities exchange commissionMirae asset global investments coGoldman sachs groupPrincipal financial group incAssociates corpBlueprint medicines corporationBlueprint medicinesFree reportGet free reportDirector jeffreyExchange commission

Blueprint Medicines (NASDAQ:BPMC) PT Raised to $104 00

Blueprint Medicines (NASDAQ:BPMC) PT Raised to $104 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesChristopherk murrayPiper sandlerStifel nicolausJeffreyw albersPolar capital holdings plcBlueprint medicines corporationNorges bankBlueprint medicines company profileNeedham companySecurities exchange commissionBlueprint medicinesFree reportModerate buyGet free reportDirector jeffrey